What is LambdaVision?
LambdaVision is a pioneering biotechnology firm focused on the development of a protein-based artificial retina designed to restore meaningful vision for individuals blinded by conditions such as retinitis pigmentosa and age-related macular degeneration. The company's core technology utilizes photoactive proteins that mimic the natural light-absorbing properties of human photoreceptor cells, effectively activating neuroreceptors in degenerated retinas. By bridging the gap between biological function and synthetic intervention, LambdaVision occupies a critical niche in the regenerative medicine sector, offering a potential breakthrough for patients who have exhausted traditional therapeutic options.
How much funding has LambdaVision raised?
LambdaVision has raised a total of $7.5M across 2 funding rounds:
Series A
$500K
Seed
$7M
Series A (2017): $500K with participation from Connecticut Innovations
Seed (2025): $7M led by Seraphim Capital and Seven Seven Six
Key Investors in LambdaVision
Seraphim Capital
A global leader in SpaceTech and deeptech investment, Seraphim provides capital and expertise to visionary entrepreneurs addressing critical global challenges.
Seven Seven Six
An early-stage venture capital firm that leverages proprietary operational systems to support high-growth technology companies through capital and strategic guidance.
Connecticut Innovations
Connecticut's strategic venture capital arm providing equity and debt financing to support the growth of innovative companies in the biosciences and technology sectors.
What's next for LambdaVision?
With the successful closure of this major strategic investment, LambdaVision is poised to transition into a more intensive phase of clinical validation and manufacturing scale-up. The company's strategic roadmap likely involves optimizing its protein-based production processes to meet the rigorous standards required for human clinical trials and eventual commercialization. Furthermore, the involvement of high-profile investors suggests a focus on long-term sustainability and the potential for broader applications of their light-sensitive protein platform. As the firm moves forward, the primary objective will be to demonstrate the safety and efficacy of its artificial retina in human subjects, thereby validating its position as a leader in the next generation of vision-restoration technologies.
See full LambdaVision company page
